Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs

by Daniele Parisi, Melissa F. Adasme, Anastasia Sveshnikova, Sarah Naomi Bolz, Yves Moreau, Michael Schroeder
Published 2020-01-01

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.

by Melissa F Adasme, Daniele Parisi, Kristien Van Belle, Sebastian Salentin, V Joachim Haupt, Gary S Jennings, Jörg-Christian Heinrich, Jean Herman, Ben Sprangers, Thierry Louat, Yves Moreau, Michael Schroeder
Published 2020-01-01